Obesity is a chronic disease defined by the World Health Organization as a "condition characterized by excessive body weight due to adipose tissue accumulation, which has a negative influence on health status". Obesity is the most common nutritional disorder in the western world, and its prevalence is constantly increasing in developing countries. In 2014, about 39% of the world adult population was overweight and about 13% obese ([@ref1]). Obesity is associated with several metabolic co-morbidities and higher mortality risk due to onset of type 2 diabetes, hypertension, cardiopathies and some cancers ([@ref1]).

In 2000, the WHO set classification criteria for obesity on the basis of body mass index (BMI). The normal range of BMI is 18.5-24.9, whereas for different types of obesity it is 25-29.9 (type I), 30-39.9 (type II) and \>40 (type III) ([@ref2]).

Most of the genes known to be associated with monogenic obesity belong to the leptin/melanocortin pathway and are expressed in the hypothalamus. They encode proteins involved in the food intake/energy expenditure balance. The adipocyte differentiation pathway, which involves several growth and transcription factors ([@ref3],[@ref4]), is also related to obesity.

Leptin is secreted by adipose tissue and binds to the leptin receptor in the hypothalamus, where it controls food intake through the melanocortin pathway. In the hypothalamus, leptin activates neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript protein (CARTPT), and inhibits neurons expressing neuropeptide Y (NPY) and Agouti related neuropeptide (AGRP). POMC is cleaved into melanocortins α-, β- and γ-MSH which bind to their receptors: MC3R and MC4R ([@ref3]).

Adipogenesis is the differentiation of adipocytes from mesenchymal stem cells. Differentiation into the adipocyte lineage is induced by chronic excessive energy intake and elevated glucose uptake. Many factors involved in this process have been identified, but PPARγ is the only factor which is necessary and sufficient for adipocyte differentiation, establishing it as the master regulator of adipogenesis ([@ref3]).

The most common form of Mendelian non syndromic obesity is associated with mutations in *MC4R*, with a prevalence in the general population of 1-5:10000. Patients with mutations in this gene can also present with hyperinsulinemia and increased linear growth ([@ref5]).

Other relatively frequent forms of obesity are associated with mutations in the leptin and the leptin receptor gene: *LEP* and *LEPR* (prevalence of both forms \<1:1000000). Patients with mutations in these genes show hyperphagia and severe early-onset obesity, and may also have immune function alterations and hypogonadotropic hypogonadism ([@ref5]). Obesity due to mutations in *POMC* has a prevalence \<1:1000000. Besides obesity, patients with *POMC* mutations show hypocortisolism, hair and skin hypopigmentation, neonatal hypoglycemia, seizures, cholestasis and voracious appetite ([@ref5]). Obesity linked to *PCSK1* mutations has a prevalence in the general population of \<1:1000000. Mutation carriers display severe early-onset obesity, hyperphagia, hypoglycemia, hypogonadotropic hypogonadism, hypocortisolism, elevated plasma levels of proinsulin and low plasma concentrations of insulin ([@ref5]).

Diagnosis is based on clinical findings and lipid panel measurements. Genetic testing is useful for confirming diagnosis and for differential diagnosis, recurrence risk calculation and prenatal diagnosis in families with a known mutation.

Mendelian non syndromic obesity can have autosomal dominant or autosomal recessive inheritance ([Table 1](#T1){ref-type="table"}). Pathogenic variants may be missense, nonsense, splicing or small indels. MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the genes listed in [Table 1](#T1){ref-type="table"}.

###### 

Genes associated with various forms of Mendelian non-syndromic obesity

  Gene        OMIM gene   Disease                                                                  OMIM disease   Inheritance   Function
  ----------- ----------- ------------------------------------------------------------------------ -------------- ------------- --------------------------------------------------------------------------------------------------------------------------------------
  *UCP3*      602044      Severe obesity, T2D                                                      601665         AR, AD        Uncoupling of oxidative phosphorylation, energy dissipation, modulation of tissue respiratory control, thermogenesis, energy balance
  *CARTPT*    602606      Obesity                                                                  601665         AR, AD        Inhibition of feeding
  *CEP19*     615586      Morbid obesity and spermatogenic failure                                 615703         AR            Required for ciliation
  *DYRK1B*    604556      Abdominal obesity-metabolic syndrome 3                                   615812         AD            Enhancement of adipogenesis
  *KSR2*      610737      Severe early-onset obesity                                               /              AD, AR        Regulation of cell energy homeostasis through AMPK activation
  *LEP*       164160      Morbid obesity                                                           614962         AR            Major role in regulation of energy homeostasis
  *LEPR*      601007      Morbid obesity                                                           614963         AR            
  *MC4R*      155541      Obesity                                                                  618406         AD, AR        
  *NR0B2*     604630      Early-onset mild obesity                                                 601665         AD, AR        Transcriptional regulator of HNF4A, involved in onset of MODY
  *PCSK1*     162150      Obesity                                                                  600955         AR            Processing of POMC, insulin
  *POMC*      176830      Obesity, adrenal insufficiency, red hair                                 609734         AR            Energy homeostasis
  *PPARG*     601487      Severe obesity                                                           601665         AD, AR        Regulator of adipocyte differentiation
  *PPP1R3A*   600917      NIDDM, obesity                                                           125853         AD            Regulation of glycogen metabolism
  *SH2B1*     608937      Hyperphagia, early onset obesity, insulin resistance and short stature   /              AD            Adaptor protein involved in insulin, BDNF and leptin signaling pathways
  *SIM1*      603128      Severe obesity, neurobehavioral disorder                                 /              AD            Transcription factors essential for formation of the hypothalamic paraventricular nucleus
  *TUB*       601197      Retinal dystrophy and obesity                                            616188         AR            Involved in hypothalamic regulation of body weight
  *NTRK2*     600456      Obesity, hyperphagia, developmental delay                                613886         AD            Mediation of neuronal plasticity in hypothalamus
  *ADCY3*     600291      Obesity, T2D                                                             /              AR            Control of adipose tissue development, function and insulin secretion in beta cells
  *BDNF*      113505      Hyperphagia, severe obesity, cognitive impairment, hyperactivity         /              AD            Regulation of food intake, body weight

AD=autosomal dominant; AR=autosomal recessive; T2D=type II diabetes; MODY=diabetes of the young; NIDDM=non-insulin dependent diabetes mellitus.

Worldwide, 34 accredited medical genetic laboratories in the EU and 37 in the US, listed in the Orphanet ([@ref5]) and GTR ([@ref6]) databases, respectively, offer genetic tests for Mendelian non syndromic obesity. The guidelines for clinical use of genetic testing are available in Genetics Home Reference ([@ref7]).

Conclusions {#sec1-2}
===========

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with Mendelian obesity. When this suspects is present we perform the analysis of all the genes present in this short article.

In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).
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